STAT3-IN-3 NEW
| Price | $892 | $1360 | $2190 |
| Package | 25mg | 50mg | 100mg |
| Supply Ability: | 10g |
| Update Time: | 2026-05-26 |
Product Details
| Product Name: STAT3-IN-3 | CAS No.: 2361304-26-7 |
| Purity: 99.49% | Supply Ability: 10g |
| Release date: 2026/05/26 |
Product Introduction
Bioactivity
| Name | STAT3-IN-3 |
| Description | STAT3-IN-3 is a potent and highly selective targeted STAT3 inhibitor with significant anti-proliferative activity. It effectively induces apoptosis in breast cancer cells. As a mitochondrially targeted STAT3 inhibitor with great research potential, it has good application value in tumor mechanism exploration and anti-cancer research. |
| In vitro | Methods: In vitro cell experiments and molecular biology assays were used to evaluate the effects of STAT3-IN-3 on the phosphorylation levels of STAT3 and its upstream and downstream related kinases, tumor cell proliferation, target gene expression, and STAT3 DNA-binding ability. Meanwhile, the levels of reactive oxygen species (ROS), mitochondrial membrane potential, and cleavage levels of apoptosis-related proteins were detected to clarify its pro-apoptotic mechanism. Results: 1.STAT3-IN-3 did not alter the phosphorylation levels of STAT1, JAK2, Src, and Erk1/2, indicating a certain degree of target specificity in its action. 2.STAT3-IN-3 significantly inhibited the proliferation of various tumor cells, with IC?? values of 1.43 μM, 1.89 μM, 2.88 μM, and 3.33 μM for MDA?MB?231, HCT?116, HepG2, and MCF?7 cells, respectively. 3.STAT3-IN-3 effectively inhibited the tyrosine and serine phosphorylation of STAT3, reduced the DNA-binding activity of STAT3, and downregulated the expression of downstream target genes Bcl-2 and Cyclin D1. 4.Treatment of cells with 1–4 μM STAT3-IN-3 for 24 hours increased intracellular ROS production, decreased mitochondrial membrane potential, thereby activating the mitochondrial apoptotic pathway. Meanwhile, it promoted the cleavage of caspase-9, caspase-3, and PARP proteins, initiating the cellular apoptotic program [1]. |
| In vivo | Methods: A 4T1 breast cancer xenograft animal model was used. STAT3-IN-3 was administered via daily intraperitoneal injection at a dose of 10 mg/kg to 20 mg/kg for 14 consecutive days, and its in vivo antitumor effect was observed and evaluated. Results: STAT3-IN-3 (10–20 mg/kg, intraperitoneal injection once daily for 14 consecutive days) significantly inhibited the growth of 4T1 breast cancer xenografts in vivo, showing good in vivo antitumor activity [1]. |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year Shipping with blue ice/Shipping at ambient temperature. |
| Solubility Information | DMSO : 4 mg/mL (6.66 mM), Sonication is recommended. |
| Keywords | STAT3-IN-3 | STAT-3-IN-3 | STAT3IN3 | STAT3 IN 3 | STAT3 |
Company Profile Introduction
Target Molecule Corp. (TargetMol) is a global high-tech enterprise, headquartered in Boston, MA, specializing in chemical and biological research product and service to meet the research needs of global customers.
TargetMol has evolved into one of the biggest global compound library and small molecule suppliers and a customer based on 40+ countries. TargetMol offers over 80 types of compound libraries and a wide range of high-quality research chemicals including inhibitors, activator, natural compounds, peptides, inhibitory antibodies, and novel life-science kits, for laboratory and scientific use. Besides, virtual screening service is also available for customers who would like to conduct the computer-aided drug discovery.
You may like
Recommended supplier
| Product name | Price | Suppliers | Update time | |
|---|---|---|---|---|
| $196.00 |
VIP6Y
|
TargetMol Chemicals Inc.
|
2026-06-12 | |
|
VIP1Y
|
ACROBiosystems
|
2026-05-11 | ||
| $892.00 |
VIP2Y
|
TargetMol Chemicals Inc.
|
2026-05-26 | |
| $1230.00 |
VIP2Y
|
TargetMol Chemicals Inc.
|
2025-07-22 |
United States- Since: 2011-01-07
- Address: 36 Washington Street, Wellesley Hill, USA
INQUIRY